|
End-of-day quote
Nasdaq
2026-09-01
|
5-day change | 1st Jan Change | ||
| 5.240 USD | +0.96% |
|
+3.76% | +2.14% |
| 08-31 | Alvotech Shares Rise After FDA Accepts Biologics License Application for AVT80 | MT |
| 08-31 | Alvotech's Application for Proposed Entyvio Biosimilar Accepted for US FDA Review | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1.85B | |||||
| 49.81B | |||||
| 44.06B | - | - | - | - | - |
| 42.99B | |||||
| 40.88B | |||||
| 33.11B |
- Stock Market
- Stocks
- ALVO Stock
- Charts Alvotech
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
